Mifamurtide

Drug Profile

Mifamurtide

Alternative Names: CGP 19835; CGP 19835A; Junovan; L-MTP-PE; Liposomal MTP-PE; Mepact; MLV 19835A; MTP-PE; Muramyltripeptide phosphatidylethanolamine

Latest Information Update: 18 Apr 2017

Price : $50

At a glance

  • Originator Novartis
  • Developer Medison Pharma; Takeda America Holdings
  • Class Antineoplastics; Drug conjugates; Ethanolamines; Immunoconjugates; Peptides
  • Mechanism of Action Macrophage stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Osteosarcoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Osteosarcoma
  • Discontinued HIV infections

Most Recent Events

  • 18 Apr 2017 Launched for Osteosarcoma (Non-metastatic) in Venezuela, South Korea, Ukraine, and Brazil (IV) before April 2017
  • 04 Nov 2016 University of Oxford completes the phase II MEMOS trial for Osteosarcoma (Metastatic disease, Second line therapy or greater) in Germany, Italy, Netherlands, Norway and United Kingdom (NCT02441309)
  • 01 Oct 2014 Registered for Osteosarcoma in Brazil (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top